Corcept's Lifyorli Shows Broad OS Benefit in Ovarian Cancer at ASCO 2026

What happened

Corcept unveiled new overall survival data from the Phase 3 ROSELLA trial at ASCO 2026, showing Lifyorli (relacorilant) plus nab-paclitaxel improved OS across all subgroups of platinum-resistant ovarian cancer, including patients with recent taxane exposure. This data bolsters the case for a regulatory filing, which the company plans to submit in Q3 2025. While the efficacy signal appears broad, the single trial nature and competition from Elahere and other therapies warrant caution. The positive readout de-risks the ovarian cancer opportunity but does not guarantee a smooth approval or commercial uptake. Investors should weigh this against the upcoming FDA decision for relacorilant in Cushing's syndrome, expected by year-end 2025.

Implication

For investors, the ASCO 2026 data incrementally supports the thesis that relacorilant has meaningful activity in platinum-resistant ovarian cancer, potentially opening a multi-billion dollar market opportunity beyond Cushing's. However, the stock already trades at a premium valuation (P/E ~73x), pricing in significant pipeline success. The data does not address other key risks such as reimbursement challenges, competition from emerging therapies, or potential hurdles in manufacturing and supply chain. Near-term attention should remain on the Cushing's PDUFA, as that is the more immediate binary catalyst. A failure or restrictive label there could overshadow the ovarian cancer progress. We maintain a cautious stance until regulatory clarity emerges, though the data marginally improves the risk/reward profile.

Thesis delta

The ASCO 2026 data modestly shifts the thesis from purely Cushing's-dependent to a more diversified pipeline story, but the core investment case remains tied to near-term regulatory outcomes. The positive survival benefit increases the probability of a successful ovarian cancer filing, potentially moving the stance from HOLD/NEUTRAL toward BUY if accompanied by clean regulatory reviews. However, execution risk and valuation leave little room for error, so we await further milestones before upgrading.